Abstract
This mini-review describes the Chemistry, Manufacturing and Control activities associated with the manufacture of [14C]-labeled drug substance and subsequent drug compounding activities to generate clinical trial material utilized in human absorption, distribution, metabolism, and excretion clinical studies. Due to the unstable nature and increased decomposition rates observed with [14C]-labeled compounds, the manufacture, testing, release, formulation, and regulatory filings are uniquely challenging. A case study of the cardiac myosin activator AMG 423 (omecamtiv mercarbil), utilized in a dual oral/intravenous infusion clinical study is presented.
Keywords: Chemistry, Manufacturing and Control (CMC), current Good Manufacturing Practice (cGMP), [14C]-Labeled Drug, Omecamtiv Mercarbil, AMG 423, human Absorption, Distribution, Metabolism, and Excretion (hADME), ICH Guidance, FDA Regulations.
Current Pharmaceutical Design
Title:Manufacturing of [14C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil
Volume: 22 Issue: 5
Author(s): Scott W. Roberts, Jeroen M. Bezemer, Michael T. Kennedy, Tiffany L. Correll, Raju Subramanian and Shawn D. Walker
Affiliation:
Keywords: Chemistry, Manufacturing and Control (CMC), current Good Manufacturing Practice (cGMP), [14C]-Labeled Drug, Omecamtiv Mercarbil, AMG 423, human Absorption, Distribution, Metabolism, and Excretion (hADME), ICH Guidance, FDA Regulations.
Abstract: This mini-review describes the Chemistry, Manufacturing and Control activities associated with the manufacture of [14C]-labeled drug substance and subsequent drug compounding activities to generate clinical trial material utilized in human absorption, distribution, metabolism, and excretion clinical studies. Due to the unstable nature and increased decomposition rates observed with [14C]-labeled compounds, the manufacture, testing, release, formulation, and regulatory filings are uniquely challenging. A case study of the cardiac myosin activator AMG 423 (omecamtiv mercarbil), utilized in a dual oral/intravenous infusion clinical study is presented.
Export Options
About this article
Cite this article as:
Roberts W. Scott, Bezemer M. Jeroen, Kennedy T. Michael, Correll L. Tiffany, Subramanian Raju and Walker D. Shawn, Manufacturing of [14C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil, Current Pharmaceutical Design 2016; 22 (5) . https://dx.doi.org/10.2174/1381612822666151228104826
DOI https://dx.doi.org/10.2174/1381612822666151228104826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Relationship between Augmentation Index and Wall Thickening Fraction during Hypotension in an Animal Model of Myocardial Ischemia-Reperfusion and Heart Failure
Current Hypertension Reviews Epidemiology of Septic Acute Kidney Injury
Current Drug Targets Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Biomarkers Associated with Atrial Fibrosis and Remodeling
Current Medicinal Chemistry Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Current Medicinal Chemistry Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement
Current Cardiology Reviews The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology The Role of Angiotensin Type 1 Receptor in Inflammation and Endothelial Dysfunction
Recent Patents on Cardiovascular Drug Discovery Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Low Lymphocyte Count and Cardiovascular Diseases
Current Medicinal Chemistry Natural Plants with Antiepileptic Activity-The Present and Future Perspectives
The Natural Products Journal